L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus
About this trial
This is an interventional treatment trial for PD-1 Antibody
Eligibility Criteria
Inclusion Criteria: Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis. EBV-DNA in peripheral blood > 1000 copies/ml or EBER detected in tissue specimens. Age 18~65,gender is not limited. Estimated survival time ≥ 1 month. Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index >250. Signed informed consent. Exclusion Criteria: Heart function above grade II (NYHA). Severe myocardial injury:TNT、TNI、CK-MB > 3 ULN. Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease. Pregnancy or lactating Women. Allergic to pegylated liposomal doxorubicin,etoposide,or PD-1 antibody. Thyroid dysfunction. HIV antibody positivity. Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable). Participate in other clinical research at the same time. The researchers considered that patients are not suitable for the study.
Sites / Locations
- Beijing Friendship Hospital, Capital Medical University
Arms of the Study
Arm 1
Experimental
L-DEP and PD-1 antibody
PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles